Long-Term Clinical Remission in a Patient with Metastatic Gastric Cancer after Palliative Chemotherapy

2000 ◽  
Vol 23 (5) ◽  
pp. 464-466 ◽  
Author(s):  
A. Teufel ◽  
T. Lehnert ◽  
W. Stremmel ◽  
J. Rudi
Keyword(s):  
Gastric Cancer ◽  
Clinical Remission ◽  
Palliative Chemotherapy ◽  
Metastatic Gastric Cancer

scholarly journals Factors Affecting Long Term Survival for Metastatic Gastric Cancer Treated with Chemotherapy

2016 ◽  
Vol 16 (2) ◽  
pp. 97
Author(s):  
Seong Kyeong Lim ◽  
Kyoungwon Jung ◽  
Moo In Park ◽  
Jae Hyun Kim ◽  
Sung Eun Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Factors Affecting

Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy

2007 ◽  
Vol 42 (7) ◽  
pp. 533-538 ◽  
Author(s):  
Ayumu Hosokawa ◽  
Toshiro Sugiyama ◽  
Atsushi Ohtsu ◽  
Toshihiko Doi ◽  
Santa Hattori ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Long Term Outcomes

scholarly journals Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5934
Author(s):  
Romy M. van Amelsfoort ◽  
Karen van der Sluis ◽  
Winnie Schats ◽  
Edwin P. M. Jansen ◽  
Johanna W. van Sandick ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Locally Advanced Gastric Cancer ◽  
Related Quality ◽  
Health Related ◽  
Gastric Cancer Patients

Background: Current treatment strategies have been designed to improve survival in locally advanced gastric cancer patients. Besides its impact on survival, treatment also affects health-related quality of life (HRQOL), but an overview of reported studies is currently lacking. The aim of this systematic review was therefore to determine the short- and long-term impact of chemotherapy, surgery, and (chemo)radiotherapy on HRQOL in locally advanced, non-metastatic gastric cancer patients. Methods: A systematic review was performed including studies published between January 2000 and February 2021. We extracted studies published in Medline, Embase, and Scopus databases that assessed HRQOL in patients with locally advanced, non-metastatic gastric cancer treated with curative intent. Studies using non-validated HRQOL questionnaires were excluded. Short-term and long-term HRQOL were defined as HRQOL scores within and beyond 6 months after treatment, respectively. Results: Initially, we identified 8705 articles (4037 of which were duplicates, i.e., 46%) and ultimately included 10 articles. Most studies reported that short-term HRQOL worsened in the follow-up period from 6 weeks to 3 months after surgery. However, recovery of HRQOL to preoperative levels occurred after 6 months. After completion of chemoradiotherapy, the same pattern was seen with worse HRQOL after treatment and a recovery of HRQOL after 6–12 months. Conclusions: In patients with locally advanced, non-metastatic gastric cancer, HRQOL deteriorated during the first 3 months after surgery and chemoradiotherapy. However, the long-term data showed a recovery of HRQOL after 6–12 months. To implement HRQOL in clinical decision making in current clinical practice, more research is needed.

The clinical response to preoperative chemotherapy is associated with improved long-term outcomes of patients with non-metastatic gastric cancer

2020 ◽  
Vol 46 (2) ◽  
pp. e136
Author(s):  
Augustinas Bausys ◽  
Martynas Luksta ◽  
Justas Kuliavas ◽  
Giedre Anglickiene ◽  
Edita Baltruskeviciene ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Response ◽  
Preoperative Chemotherapy ◽  
Metastatic Gastric Cancer ◽  
Long Term Outcomes

Class III β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 44-44
Author(s):  
Jun-Eul Hwang ◽  
Dae-Eun Kim ◽  
Hyun-Jeong Shim ◽  
Woo Kyun Bae ◽  
Sang-Hee Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Palliative Chemotherapy ◽  
Predictive Marker ◽  
Metastatic Gastric Cancer ◽  
Class Iii ◽  
First Line ◽  
Gastric Cancer Patients ◽  
Low Expression ◽  
Β Tubulin

44 Background: Class III β tubulin (TUBB3) is a prognostic marker in various tumors and role of TUBB3 in advanced gastric cancer is not clearly defined yet. We analyzed the significance of TUBB3 expression along with ERCC1 in recurrent or metastatic gastric cancer patients receiving taxane based first-line palliative chemotherapy. Methods: We reviewed 146 patients with advanced gastric adenocarcinoma who received taxane based first-line palliative chemotherapy between 2004 and 2010 at Chonnam National University Hwasun hospital. Immunohistochemical stain of TUBB3 and ERCC1 was done in paraffin-embedded tumor tissue. We evaluated response to chemotherapy, progression-free survival (PFS), and overall survival (OS). Results: A total of 146 patients with advanced gastric cancer received docetaxel and cisplatin (n=15), or paclitaxel and cisplatin (n=131) with or without 5-fluorouracil (5-FU). The median PFS was significantly shorter for patients with TUBB3 high expression than patients with TUBB3 low expression (3.63 versus 6.67 months, p=0.001). OS was not associated with TUBB3 expression status (12.9 versus 13.1 months, p=0.769). In multivariate analysis, only TUBB3 was related to shorter PFS (HR 2.74, 95% CI 1.91-3.91, p=0.001). Patients with ERCC1 high expression showed lower response rate than patients with ERCC1 low expression (24% versus 63.2%, p=0.001), however ERCC1 showed no clinical influence on PFS and OS. Conclusions: TUBB3 is a strong predictive marker in recurrent or metastatic gastric cancer patients receiving taxane based first-line palliative chemotherapy. Clinical impact of ERCC1 is not evident in this setting.

Comparison of outcomes for the elderly patients treated with single agent versus doublet regimen as first-line chemotherapy for recurrent or metastatic gastric cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 136-136
Author(s):  
Der Sheng Sun ◽  
Yoon Ho Ko ◽  
Eun Kyoung Jeon ◽  
Hye Sung Won ◽  
Byoung Young Shim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Palliative Chemotherapy ◽  
Performance Status ◽  
Single Agent ◽  
Dose Intensity ◽  
The Elderly ◽  
Metastatic Gastric Cancer ◽  
Hematologic Toxicity ◽  
First Line ◽  
Line Chemotherapy

136 Background: Gastric cancer (GC) is a second leading cause of death in Korean elderly cancer patients. Palliative chemotherapy would be an option of treatment in inoperable elderly GC patients for gaining survival time. We analysed the differences between single and doublet first line palliative chemotherapy in elderly GC patients. Methods: More than 70-year-old GC patients treated in the hospitals of the Catholic university of Korea were analysed. Baseline characteristics, first-line chemotherapy regimen, treatment responses, toxicities, time to progression (TTP) and overall survival (OS) were evaluated. Results: From 2005 to 2012, 178 GC patients above 70 years had been treated with palliative chemotherapy with single or doublet regimen. The median age were 77 years (range 70-89) in single regimen group (SG, 70 patients) and 73 years (range 70-81) in doublet regimen group (DG, 108 patients). TS-1 or capecitabine was used in SG, and platinum combined with 5FU or taxane was the most common regimen in DG. The most common response in both group was stable disease. Median relative dose intensity was 92.4% (range 50~100%) in SG and 83.5% (range 43~100%) in DG. Median TTP in SG was 4.40 months (95% CI, 2.85-5.95) and 4.10 months in DG (95% CI, 2.62-5.57, P=0.295). Median OS was 6.90 months (95% CI, 4.20-9.59) in SG, 8.20 months (95% CI, 5.96-10.43, p=0.918) in DG. Hematologic (P=0.03) and non-hematologic toxicities (p=0.061) were more frequent in DG. The common causes to terminate chemotherapy were disease progression in SG and decreased performance status in DG. Conclusions: No significant differences were observed in TTP and OS in both groups, but treatment related hematologic toxicity of SG was less than DG. Single agent treatment would be considered as the option of first line palliative chemotherapy in the elderly more than 70 years.

scholarly journals Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment

2019 ◽  
Vol 28 (4) ◽  
pp. 503-507 ◽  
Author(s):  
Tobias Gutting ◽  
Nadine Schulte ◽  
Sebastian Belle ◽  
Johannes Betge ◽  
Nicolai Härtel ◽  
...  
Keyword(s):  
Palliative Chemotherapy ◽  
Stage Iv ◽  
Immunohistochemical Analysis ◽  
Complete Response ◽  
Metastatic Gastric Cancer ◽  
Microcytic Anemia ◽  
Poor Clinical Outcome ◽  
Multiple Liver Metastases ◽  
Trastuzumab Monotherapy

Metastatic gastric cancer (GC) and oesophagogastric junctional (OGJ) adenocarcinoma have a poor clinical outcome with a high worldwide burden of disease. A 65-year old male patient with microcytic anemia was diagnosed with stage IV OGJ adenocarcinoma with multiple liver metastases. Immunohistochemical analysis revealed a high expression of HER2 (3+). Palliative chemotherapy with FLOT (oxaliplatin, 5-fluorouracil, leucovorin and docetaxel) in combination with trastuzumab was initiated. Due to severe adverse events, the therapy was de-escalated to trastuzumab monotherapy after six months of treatment. Initial restaging revealed partial response after the combination therapy of FLOT with trastuzumab. After reduction to trastuzumab monotherapy, the disease remained stable for two years until radiological complete response was observed. Trastuzumab monotherapy was continued for another two years to maintain complete response. Eleven months after the discontinuation of the therapy, no recurrence of the disease was detected. In conclusion, complete response can be achieved under trastuzumab monotherapy in exceptional responders.

Sign in / Sign up

Export Citation Format

Share Document